The safety profile of tirzepatide was consistent with other GLP-1 receptor agonists, indicating its potential as a treatment option for Japanese patients with type 2 diabetes
GHD also contributes to the alteration of body composition and weight gain, with decreased lean mass, increased FM, mainly truncal FM with increase waist/hip ratio, scarce muscle tone and strength, reduced energy expenditure, and exercise tolerance [45,46,47]
What are the typical side effects of CJC-1295
Retatrutide as the Reference Triple Agonist Retatrutide is the first triple agonist peptide to reach Phase 2 and Phase 3 clinical trials, and remains the reference compound for the category
Patients who adopt smaller, more frequent meals with lower fat content typically report fewer and less severe symptoms